NASDAQ$IMNM

Immunome Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Immunome reported Q4 2024 a net loss of $293.0M.

For Q4 2024, Immunome reported net loss was $293.0M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Net loss $293.0M.
  • MD&A highlights operating priorities, liquidity, and sector risks.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$9.04K

Previous: $3.83M-99.8%
EPS (adj)

-$5.00

Previous: -$0.15-3233.3%
R&D Expenses

$37.2M

Previous: $23.1K+161015.7%
G&A Expenses

$9.53M

Previous: $19.7K+48361.1%
IPR&D Expenses

$6.71M

Previous: $80.8K+8199.3%
Interest Income

$3.42M

Previous: $2.72K+125524.1%
Weighted Avg Shares

60.2M

Previous: 19.8M+203.4%
Net Income

-$293M

Previous: -$92.6M-216.3%
Operating Income

-$306K

Previous: -$94.7M+99.7%

Revenue & EPS history

Immunome · Revenue · Quarterly

$9.04K

Q4 2024-99.8%vs Q4 2023
Beat estimate in 2 of 9 quarters(22%)
ActualEstimate

Forward guidance

Outlook emphasizes clinical milestones, cash runway, and R&D spend.

Tailwinds

  • Pipeline progress and partnership economics.
  • Balance-sheet flexibility where noted in the release.

Headwinds

  • Operating losses until commercialization.
  • Trial, regulatory, and financing risks.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.8%

Avg return

Earnings day

-2.4%

Avg return

5 days after

+0.6%

Avg return

30 days after

32%

7 / 22 earnings

Positive

+24.1%

Q4 2021

Best reaction

-10.8%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.3%-9.1%-20.0%
Q4 2025+4.7%-1.0%+1.4%
Q3 2025-5.0%+2.5%+12.3%
Q1 2025+1.1%-1.0%+15.0%
Q4 2024-4.0%-18.9%-7.7%
Q3 2024-10.8%-24.5%+0.7%
Q2 2024+4.7%+4.7%+11.9%
Q1 2024-1.3%-6.2%-3.2%
Q4 2023-2.3%-16.2%-46.2%
Q3 2023-8.1%-8.9%-12.2%
Q2 2023-1.9%-0.8%+3.9%
Q1 2023+2.3%+11.9%-6.2%
Q4 2022+20.8%+18.9%+2.3%
Q3 2022+0.0%-27.6%-8.5%
Q2 2022+19.3%+13.6%+24.7%
Q1 2022-2.6%+19.6%+46.5%
Q4 2021+24.1%+20.1%-26.3%
Q3 2021-1.0%-5.1%-9.3%
Q2 2021-3.2%-11.9%+51.2%
Q1 2021-10.7%-3.0%-2.9%
Q4 2020-1.0%-4.3%-8.3%
Q3 2020-5.5%-6.4%-6.1%
Q2 2020
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro